Please read and agree to the terms and conditions of this site.
@xconomy.com 3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com 3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com 4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com 5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com 5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com 5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision